R M Guevin - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Filters

R M Guevin

Showing results (1-10 of 3) with videos related to

Pageof 1

Sort By:

Vox Sanguinis|January 1, 1975

Australia antigen 'ad' and 'ay' subtypes. Purification and partial characterizationR Bourbonnais, R M Guevin, E E Delvin

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1997

Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapyW S Lofters, J L Pater, B Zee, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1997

The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapyJ L Pater, W S Lofters, B Zee, et al.

Pageof 1

Search research articles

Showing results (1-10 of 3) with videos related to

Sort By:

Pageof 1

Vox Sanguinis|January 1, 1975

Australia antigen 'ad' and 'ay' subtypes. Purification and partial characterizationR Bourbonnais, R M Guevin, E E Delvin

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1997

Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapyW S Lofters, J L Pater, B Zee, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1997

The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapyJ L Pater, W S Lofters, B Zee, et al.

Pageof 1